ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
7 hedge funds and large institutions have $27.6M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
11% less capital invested
Capital invested by funds: $31M → $27.6M (-$3.41M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
MYDA Advisors
Woodmere,
New York
|
-$94.1K |
| 2 |
Millennium Management
New York
|
-$55.6K |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$2.84K |
ASLN Hedge Fund Activity: Q3 2018 in Review
7 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2018, worth a combined $27.6M — down 11% from $31M a quarter earlier.
Fund positioning in ASLN was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was MYDA Advisors, cutting an estimated $94.1K.
- 7 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $27.6M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2018, down 11% quarter-over-quarter.
- 0 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2018 and 0 closed out.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2018 was MYDA Advisors, an estimated $94.1K sold.
Based on aggregated 13F filings for Q3 2018.